• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

BARD1 Share Price is Up 83% Today — Here’s Why (ASX:BD1)

Like 0

By Ryan Clarkson-Ledward, Thursday, 11 February 2021

Despite their rather unusual moniker, BARD1 Life Sciences Ltd [ASX:BD1] is making a name for themselves today. This small biotech stock is up 83.22% at time of writing...

Despite their rather unusual moniker, BARD1 Life Sciences Ltd [ASX:BD1] is making a name for themselves today.

This small biotech stock is up 83.22% at time of writing. Surging on the back of some fantastic news for not only shareholders, but also ovarian cancer patients.

Because this small-cap may have just made a huge breakthrough…

Early and accurate detection

See, BARD1 is a diagnostics company. Focusing their efforts on ways to pinpoint and notify patients about all manner of diseases and illnesses.

Four Innovative Aussie Small-Cap Stocks That Could Shoot Up. Download your report now.

And one of their recent development products has revolved around a protein known only as SubB2M. A biomarker that BARD1, along with Griffith University, have been evaluating as a potential tool to diagnose select cancers.

In fact, in their ongoing investigation, university researchers have been able to use SubB2M to detect all stages of ovarian cancer. A diagnosis that has thus far carried 100% specificity and 100% sensitivity.

Making this patented protein a fantastic candidate for early detection of this life-threatening disease.

As CEO Dr Leearne Hinch notes:

‘The Company is focused on early detection of cancer and our SubB2M technology provides the potential for developing tests for monitoring and detection of multiple cancers.

‘We will continue to collaborate with Griffith University to develop and validate commercial assays for monitoring treatment response and recurrence in ovarian cancer patients to improve health outcomes for this critical unmet medical need.’

It could be a huge breakthrough. One that could net this company a whole lot of revenue if they can successfully develop said test kits.

Plus, with this may just be the first of more wins to come. After all, SubB2M may be just as effective at detecting other cancers as well. At the very least, BARD1 will certainly be looking to explore that possibility.

What’s next for BARD1 Share Price?

With these early results now in, the focus will no doubt remain on further investigation. Exploring the full potential and possibilities of this unique protein.

Then, once the arduous testing is out of the way, BARD1 will need to find a way to create accessible test kits. Whether they be for personal or professional use.

So, with that in mind, it could still be some time before this technology actually becomes commercially available.

Nevertheless, it is something that shareholders will be watching eagerly. With some fantastic potential for this biotech to become a serious contender in massive healthcare industry.

And if you’re looking for more small-cap news and insights — be it in biotech or beyond — you should check out our daily e-letter Money Morning. A publication that presents the stories you need to know, that the mainstream isn’t willing or fit to cover.

For more information, click here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988